Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Public ClinicalTrials.gov record NCT04567329. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Multi-Center, Randomized, Double-Masked, Saline-Controlled Trial to Evaluate the Effect of NOV03 on Signs and Symptoms of Dry Eye Disease Associated With Meibomian Gland Dysfunction (Mojave Study)
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The objectives of this trial are to assess the efficacy, safety, and tolerability of NOV03 ophthalmic solution in comparison to a saline control for the treatment of the signs and symptoms of Dry Eye Disease (DED) associated with Meibomian Gland Dysfunction (MGD).
Study identification
- NCT ID
- NCT04567329
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 620 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 18, 2020 (Actual)
- Primary completion
- Aug 30, 2021 (Actual)
- Completion
- Aug 30, 2021 (Actual)
- Last update posted
- Aug 19, 2024
2020 – 2021
United States locations
- U.S. sites
- 35
- U.S. states
- 18
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Bausch Site 206 | Phoenix | Arizona | 85032 | — |
| Bausch Site 202 | Garden Grove | California | 92843 | — |
| Bausch Site 221 | Hemet | California | 92545 | — |
| Bausch Site 214 | Inglewood | California | 90301 | — |
| Bausch Site 226 | Murrieta | California | 92562 | — |
| Bausch Site 213 | Santa Ana | California | 92705 | — |
| Bausch site 236 | Westminster | California | 92683 | — |
| Bausch site 225 | Grand Junction | Colorado | 81501 | — |
| Bausch Site 211 | Delray Beach | Florida | 33484 | — |
| Bausch Site 204 | Morrow | Georgia | 30260 | — |
| Bausch Site 209 | Chicago | Illinois | 60616 | — |
| Bausch site 218 | Hoffman Estates | Illinois | 60169 | — |
| Bausch Site 230 | Overland Park | Kansas | 66210 | — |
| Bausch Site 207 | Louisville | Kentucky | 40220 | — |
| Bausch Site 228 | Havre de Grace | Maryland | 21078 | — |
| Bausch Site 231 | Bloomington | Minnesota | 55431 | — |
| Bausch Site 229 | St Louis | Missouri | 63128 | — |
| Bausch Site 224 | St Louis | Missouri | 63131 | — |
| Bausch Site 217 | Washington | Missouri | 63090 | — |
| Bausch Site 208 | Rochester | New York | 14618 | — |
| Bausch Site 210 | Asheville | North Carolina | 28803 | — |
| Bausch site 233 | High Point | North Carolina | 27262 | — |
| Bausch site 232 | Southern Pines | North Carolina | 28387 | — |
| Bausch Site 201 | Cincinnati | Ohio | 45247 | — |
| Bausch Site 216 | Cleveland | Ohio | 44115 | — |
| Bausch Site 223 | Columbus | Ohio | 43215 | — |
| Bausch Site 215 | Nashville | Tennessee | 37215 | — |
| Bausch site 235 | Austin | Texas | 78731 | — |
| Bausch Site 219 | Cedar Park | Texas | 78613 | — |
| Bausch Site 212 | League City | Texas | 77573 | — |
| Bausch site 234 | San Antonio | Texas | 78209 | — |
| Bausch Site 222 | San Antonio | Texas | 78215 | — |
| Bausch Site 203 | San Antonio | Texas | 78230 | — |
| Bausch Site 220 | Norfolk | Virginia | 23502 | — |
| Bausch Site 227 | Seattle | Washington | 98119 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04567329, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 19, 2024 · Synced Oct 21, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04567329 live on ClinicalTrials.gov.